Търсене на изпитвания

Активни:

Намерени 4,781 изпитвания Стр. 202 от 240

Активно (без набиране)

Effect of Hand Massage Stimulation on Pain and Menstrual Symptoms in Primary Dysmenorrhea

Dysmenorrhea

Purpose of this study: The purpose of this study is to determine the effect of hand massage stimulation techniques on pain, daily menstrual symptoms and nausea and vomiting in primary dysmenorrhea. H1a: Hand massage stimulation techniques reduce pain in primary dysmenorrhea. H1b: Hand massage stimulation techniques reduce daily menstrual symptoms in primary dysmenorrhea. The data were collected from students suffering from primary dysmenorrhea pain studying at İnönü University Faculty of Health Sciences. Seed therapy (su-jok) will be applied by researcher Esra Tan, who has a basic level su-jok therapy certificate.

Начало: 01.09.2025 Край: 01.09.2026 Възраст: 18–50 г.

Turkey (Türkiye) Inonu University NCT07544511

Активно (без набиране) Фаза 2

24VA022; VATCH Alpelisib for TIE2/PIK3CA Pathway VAs

Vascular Anomalies Vascular Anomaly TIE2/PIK3CA Pathway Driven Vascular Anomalies

The study will enroll participants 2 months of age up to 30 years of age. The purpose of this study is to assess the effectiveness and safety of Alpelisib (the "Study Drug") in patients with PIK3CA/TIE-2/TEK pathway driven vascular anomalies (VA). Alpelisib has been approved by the U.S. Food and Drug Administration (FDA) for treating adults and children with certain types of breast cancer. Its use in this study is considered experimental because FDA has not approved the study drug for treating people with VAs. Study participation will last for up to 3 years and will involve regular study visits to Children's Hospital of Philadelphia (CHOP)'s Philadelphia Campus. Participants will need to take the study drug Alpelisib for at least 2 years, or up to 3 years in total if there is a positive response. Participating in this research means you will attend up to 16 clinic visits for the purposes of the study. Most visits will take approximately 30 minutes, but some visits will take approximately 2 hours, because you will be asked to complete questionnaires about your experience. Participating in this research also means taking the study drug, having pictures taken, and completing study drug diaries. There is also an optional portion to this study that involves collecting blood for biomarker testing.

Начало: 27.08.2025 Край: 27.08.2030 Възраст: 2–30 г.

United States Children's Hospital of Philadelphia NCT07543822

Активно (без набиране) Фаза 2

24VA021; VATCH Trametinib for Ras/MAPK Pathway VAs

Ras/MAPK Pathway Vascular Anomalies Vascular Anomalies Vascular Anomaly

The purpose of this study is to assess the effectiveness and safety of Trametinib (the "Study Drug") in patients with Ras/MAPK pathway driven vascular anomalies (VA). Trametinib has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic melanoma. Its use in this study is considered experimental because the FDA has not approved the study drug for treating people with VAs. The study will enroll participants 2 months of age up to 30 years of age that have been diagnosed with Ras/MAPK pathway driven vascular anomalies. Study participation will last up to 3 years and will involve regular study visits to Children's Hospital of Philadelphia (CHOP) Philadelphia Campus. Participants will need to take the study drug Trametinib for at least 2 years, or up to 3 years in total, if there is a positive response. Participating in this research means you will attend up to 16 clinic visits. Most visits will take approximately 30 minutes, but some visits will take approximately 2 hours, because you will be asked to complete questionnaires about your experience. Participating in this research also means taking the study drug, having pictures taken, and completing study drug diaries. There is also an optional portion to this study that involves collecting blood for biomarker testing.

Начало: 27.08.2025 Край: 27.08.2030 Възраст: 2–30 г.

United States Children's Hospital of Philadelphia NCT07549646

Активно (без набиране) Фаза 4

Longitudinal Tracking of Bone Marrow Plasma Cell Responses to Licensed Human Vaccines

Immunology Healthy Adults

This study is being done to understand and measure how the immune system responds to and remembers different types of vaccines. To do this, four vaccines approved by the U.S. Food and Drug Administration (FDA) will be given simultaneously to participants. Participants will be volumteers who are healthy adults (18 years old or older) and willing to receive the yearly trivalent inactivated influenza vaccine (TIV), the tetanus, diphtheria, and acellular pertussis vaccine (Tdap), the nonvalent HPV (HPV) vaccine, hepatitis A virus (HAV) vaccine and undergo study procedures. Procedures will include: * medical history relevant to the study, including medications and vaccines received. * Vitals (blood pressure, pulse) and temperature * Height and weight. * Physical exams. * Receive the TIV, Tdap, HPV, and HAV vaccines. * Blood samples collected for immunologic tests and genetic analysis. * Donate bone marrow by needle aspiration at a maximum of seven visits. * Complete memory aid every evening for 7 days after vaccination Optional Procedures include: * Donate bone marrow core biopsies at the same visits * Ultrasound of lymph nodes and fine needle aspirates of lymph nodes in both arm pits at a maximum of eight separate visits There will be a screening visit and and a Day 1 where vaccinations will occur and subsequent visits at Day 8, Day 14, Day 29, Day 57, Day 121, Day 181, Day 366, Day 546, and Day 731. At each of these visits health status, vital signs and blood collection will occur. A bone marrow aspirate and lymph node aspirate will be collected at screening. The six additional bone marrow aspirates will be repeated at D29, D91, D181, D366, D546, and D731. The optional bone marrow core biopsy will also be repeated at that time. Up to seven separate visits will be scheduled for the follow-up lymph node aspirates (D29, D57, D91, D181, D366, D546, and D731) Study participation will be 24 months.

Начало: 26.08.2025 Край: 01.08.2027 Възраст: от 18 г.

United States Washington University School of Medicine NCT07493460

Активно (без набиране) Фаза 2

A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis

Rheumatoid Arthritis

This study aims to evaluate the efficacy of BGB-45035 in adults with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) or biologic disease-modifying antirheumatic drugs (bDMARDs)/targeted synthetic disease-modifying antirheumatic drugs (tsDMARDs).

Начало: 21.08.2025 Край: 18.10.2026 Възраст: от 18 г.

China BeiGene NCT07100938

Активно (без набиране) Фаза 1

Safety, Reactogenicity, and Immunogenicity Trial of STX-S SARS-CoV-2 Vaccine in Adults

COVID-19

This phase 1 clinical trial will evaluate the safety, reactogenicity, and immunogenicity of STX-S in adults who have previously received a primary series and at least one booster with an authorized or licensed SARS-CoV-2 parenteral vaccine. The study is designed as a non-randomized, open-label, dose-escalation clinical trial evaluating three dose levels of STX-S. A sample size of 60 participants (20 participants per dose cohort) is anticipated. The primary objective is to evaluate the safety and reactogenicity of a single intramuscular injection of three different dose levels (25 ng, 50 ng, and 125 ng) of STX-S in previously vaccinated healthy adults

Начало: 11.08.2025 Край: 15.06.2026 Възраст: 18–64 г.

United States National Institute of Allergy and Infectious Diseases ( NCT07095231

Активно (без набиране)

Pharmacist Intervention to Improve Smoking Cessation

Smoking Cessation

The goal of this study is to assess the effectiveness of a remote pharmacist intervention to help smokers quit. The main questions it aims to answer are: * Will smokers being screened for lung cancer with low-radiation-level chest computed tomography (CT) be willing to participate in this study and talk to the pharmacist about smoking cessation? * Will those in the intervention group be more likely to report smoking cessation than those in the control group. Participants in the intervention group will be asked to complete a baseline survey; speak with a pharmacist via phone call at baseline, 2 weeks, 4 weeks, 6 weeks, 8 weeks, 10 weeks, and 12 weeks; and complete an exit survey. Participants in the control group will be asked to complete a baseline survey and an exit survey.

Начало: 11.08.2025 Край: 01.06.2026 Възраст: 18–100 г.

United States University of Iowa NCT06943287

Активно (без набиране)

Ferric Sulfate and Sodium Hypochlorite Pulpotomies in Vital Primary Teeth

Dental Caries Pulpotomies Primary Teeth

This study aims to compare the clinical and radiographic success of two commonly used pulpotomy agents, ferric sulfate (FS) and sodium hypochlorite (NaOCl), in vital primary molars. Pulpotomy is a widely used vital pulp therapy procedure in pediatric dentistry to preserve primary teeth until their natural exfoliation. The study will include children aged 4-9 years who previously received pulpotomy treatment using either FS or NaOCl at Marmara University Faculty of Dentistry. No additional treatment will be performed as part of this study. Patients will be followed during routine clinical visits at 6, 12, and 24 months. Clinical outcomes such as pain, mobility, and infection, as well as radiographic findings including resorption and radiolucency, will be evaluated. The results of this study are expected to provide evidence for the effectiveness of these materials and support clinical decision-making in pediatric dental practice.

Начало: 10.08.2025 Край: 10.02.2027 Възраст: 4–9 г.

Turkey (Türkiye) Marmara University NCT07548008

Активно (без набиране) Фаза 2

A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF)

Desmoid Tumor Aggressive Fibromatosis

This study is being conducted to characterize the efficacy and safety of nirogacestat in Japanese adults with progressing desmoid tumors/aggressive fibromatosis.

Начало: 08.08.2025 Край: 31.10.2029 Възраст: от 18 г.

Japan SpringWorks Therapeutics, Inc. NCT07170644

Активно (без набиране) Фаза 2

Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers

Lymphoma, Non-Hodgkin Leukemia, Lymphocytic, Chronic, B-Cell B-cell Lymphoma

The purpose of this study is to find out more about the long-term safety of pirtobrutinib in participants with previously treated types of blood cancer. Participants must have chronic lymphocytic leukemia, small lymphocytic lymphoma, or non-Hodgkins lymphoma. The study is open to those who completed the original study - J2N-MC-JZNJ (NCT04849416) and continue to benefit from treatment. Treatment will be given every 12 weeks and this study is expected to last about 5 years.

Начало: 07.08.2025 Край: 01.05.2030 Възраст: от 18 г.

China Eli Lilly and Company NCT07162181

Активно (без набиране)

VR Learning Program for Sexual-and-gender-diversity Care

Sex Difference Virtual Care Nursing Care

The study is designed to create a VR learning program for sexual-and-gender-diversity care and compare the short-term and long-term effects on caring behaviors in nursing students.

Начало: 01.08.2025 Край: 31.07.2027 Възраст: от 18 г.

Taiwan National Yang Ming Chiao Tung University Hospital NCT07535216

Активно (без набиране)

Learning How to Implement and Use a Ketogenic Diet to Improve Mental Health

Medical Keto Diet

The goal of the study is to implement a team-based "train the trainer" group approach by providing participants education and the opportunity for self-implementing a medical ketogenic diet study for 4 weeks. The overarching goal of the program is for those participating to be able to initiate the diet in clinical and research settings with greater competence. The study has two parts: 1. Mastery Class (Education, Q \& A) 2. 4 Week Open Label LIVE IT ketogenic diet participation with private and group consultation (optional)

Начало: 01.08.2025 Край: 01.07.2026 Възраст: 18–74 г.

United States University of Maryland, Baltimore NCT07116226

Активно (без набиране)

Reporting Back Pesticide Results to Family Child Care Home Directors

Pesticide Exposure Community-based Family

Child Care Health Consultants will provide an integrated pest management (IPM) intervention for \~30 family child care home directors. The intervention will include an educational component, collecting carpet dust samples, reporting back the pesticides identified in the carpet, and 7-monthly consultations to identify ways to reduce their exposure to pesticides and lower their long term health risks.

Начало: 01.08.2025 Край: 28.04.2028 Възраст: 18–80 г.

United States University of California, San Francisco NCT06910462

Активно (без набиране)

The Brain&Senses Study

Mild Cognitive Impairment Alzheimer Disease Parkinson

The aim of this longitudinal observational study is to evaluate the impact of sensory deficits (smell, hearing and balance on cognitive decline and quality of life in the medium term (5 years)) on a population of patients over 55. Patients will be evaluated by a neurologist, a neuropsychologist and an otolaryngologist who will perform olfactory, auditory and vestibular tests. The acquired data will then be analyzed with multivariate analysis to understand the effect of multisensory deficit on both cognition and quality of life with a particular focus on depression. The primary objective will be the evaluation of multiple deficits on cognition, the secondary will be aimed at understanding whether one sensory deficit more than another, e.g. smell versus hearing, will have a greater impact on the patient's conditions.

Начало: 01.08.2025 Край: 30.06.2031 Възраст: 60–85 г.

Italy University of Campania Luigi Vanvitelli NCT06991816

Активно (без набиране)

Tyrosine Vs Tacrolimus With NB-UVB in Vitiligo

Vitiligo

The goal of this clinical trial is to learn if adding topical tacrolimus or topical tyrosine to narrowband UVB phototherapy works to treat vitiligo in adults. It will also learn about the safety of both combinations. The main questions it aims to answer are: Which combination (UVB + tacrolimus or UVB + tyrosine) leads to greater skin repigmentation (color return) after 3 months of treatment? What side effects do participants experience with each combination? Researchers will compare three groups: UVB + tacrolimus, UVB + tyrosine, and UVB only to see which is more effective and safer. Participants will: Receive narrowband UVB phototherapy sessions two times per week at minimal erythema dose Apply either topical tacrolimus or topical tyrosine to their vitiligo patches twice daily Visit the clinic every one month for skin examination and photography Report any side effects or skin reactions

Начало: 01.08.2025 Край: 10.04.2026 Възраст: 18–65 г.

Egypt Minia University NCT07532330

Активно (без набиране)

Complementary Behavioral Interventions To Remediate Cognitive Impairment or Emotional Distress in Cancer Survivors

Survivors of Childhood Cancer

Childhood cancer survivors are at risk for accelerated aging due to the specific treatments they have received to cure their cancer. Several interventions, including exercise, cognitive training, and mindfulness practice, have been developed and studied for effectiveness among participants in the St. Jude Lifetime Cohort (SJLIFE) to mitigate these effects. The interventions offered thus far have not included two components at the same time. The purpose of this study is to determine whether or not adult cancer survivors enrolled in SJLIFE will participate in two interventions at the same time. The combined interventions will include exercise plus cognitive training or exercise plus mindfulness practice. Each intervention will be conducted over a 12-week period. Participants will also be asked to complete follow-up testing after the 12-week intervention period is completed. Primary Objectives • To determine the acceptability of a two-component intervention (exercise (EX) plus cognitive training (CT) or exercise (EX) plus mindfulness practice (MP)) among survivors of childhood cancer with either cognitive impairment or emotional distress. Hypotheses: * 45% of those approached for participation in each arm of this study will enroll on the study. * Among those who enroll, 70% will complete the follow-up testing at 12 weeks. * Among those who completed the follow-up testing, the mean attendance to the intervention sessions will be 70% on each of their two interventions. That is, they will complete 70% of exercise sessions and 70% of either cognitive training or mindfulness practice. * To identify barriers and facilitators to intervention adherence. Hypotheses: * Participants will identify features of the study processes that either facilitate or discourage adherence. * Participants will identify features of the intervention technology and intervention components that either facilitate or discourage adherence. * Participants will identify personal factors that facilitate or discourage adherence.

Начало: 29.07.2025 Край: 01.11.2026 Възраст: от 18 г.

United States St. Jude Children's Research Hospital NCT06989463

Активно (без набиране)

Video-Intervention to Inspire Treatment Adherence for Life for Adolescents

HIV/AIDS

This a two-arm randomized controlled trial whose objective is to explore the impact of VITAL Start for Adolescents (VS4A), a video-based antiretroviral treatment (ART) adherence intervention, on a range of implementation and effectiveness outcomes. The study will be conducted in health facilities which provide HIV care to teens/adolescents in the Machinga and Balaka districts of Malawi with approximately 900 teens living with HIV and their treatment supporters (dyads). Dyads will be individually randomized on a 1:1 ratio to receive either the intervention or the standard of care. The VS4A intervention is designed to support Information, Motivation, and Behavioral skills (IMB) around adolescent ART adherence as well as strategies for enhancing treatment supporter social support. The intervention consists of: 1) a two-session video package with associated activities that both the adolescent and their treatment supporter will be asked to watch and participate in; 2) ART refill for the adolescent; 3) and intensive adherence counselling for those with a high viral load. The primary outcomes are adoption of the intervention and adolescent viral load suppression. The overall hypothesis is that VS4A will achieve high adoption and improve adolescent viral suppression.

Начало: 25.07.2025 Край: 28.03.2027 Възраст: от 10 г.

Malawi Baylor College of Medicine NCT07064785

Активно (без набиране) Фаза 1

First-in-Human PfSPZ-LARC2 Vaccination/CHMI

Malaria

This randomized, double-blind, placebo-controlled, Phase 1 trial will enroll up to 22 malaria-naïve, adult participants to test safety, tolerability, immunogenicity, and efficacy of the genetically attenuated Plasmodium falciparum sporozoite vaccine (PfSPZ-LARC2) Vaccine. PfSPZ-LARC2 Vaccine is a late-arresting, replication-competent whole Plasmodium falciparum sporozoite product. We hypothesize that the PfSPZ-LARC2 Vaccine will be safe from breakthrough infection by virtue of deletion of two key parasite genes Mei2 and LINUP and may be more immunogenic and protective than previously tested early arresting sporozoite vaccines. The primary objective is to assess the tolerability and safety of administration of PfSPZ-LARC2 Vaccine, with special attention to the adequacy of attenuation.

Начало: 23.07.2025 Край: 30.03.2027 Възраст: 18–45 г.

United States National Institute of Allergy and Infectious Diseases ( NCT06735209

Активно (без набиране)

Improving Cognitive Recovery in Multiple Sclerosis

Multiple Sclerosis

This study aims to find out whether an adapted version of an existing cognitive rehabilitation program, CIRCuiTS (https://www.circuitstherapyinfo.com), can be used to improve everyday thinking skills for people with Multiple Sclerosis (MS). People living with MS have worked with the study's researchers to adapt CIRCuiTS to meet their needs. They shared the thinking challenges they experience and suggested changes to the program's content and how it is delivered. This study will test whether this adapted version can be delivered practically to people with MS in a trial setting and explore its potential benefits. The findings will help plan a larger trial testing how effective CIRCuiTS is in helping people with MS. Twenty-four people with MS will take part in this pilot trial. Each person will be randomly assigned to start the program either right away or after a 13-week wait. The therapy program involves up to 36 hours of therapist-led and independent sessions over 12 weeks in which the participant builds thinking skills through developing personal strategies for carrying out digital versions of tasks they find challenging. The practicality of delivering the program to people with MS will be judged based on whether problems arise in the trial, such as not being able to recruit enough people or participants not liking it. To explore its potential benefits, the study will check for improvements in progress toward personal goals, thinking abilities, emotional well-being, chronic tiredness, and daily living skills after the therapy. If delivering CIRCuiTS to people with MS is found to be both practical and acceptable to participants, the findings of this trial will be used to design a larger-scale trial of its effectiveness. Ultimately, the goal of this project is to improve the quality of life of people living with cognitive difficulties related to MS.

Начало: 17.07.2025 Край: 15.09.2026 Възраст: от 18 г.

United Kingdom King's College London NCT06877273

Активно (без набиране)

LEAF(Liver Tumor dEtection And classiFication AI)

Hepatocellular Carcinoma

This study plans to utilize multiphase contrast-enhanced and non-contrast CT（Computed Tomography） images from 10000 pathologically confirmed liver tumor patients at our hospital. An AI（artificial intelligence） model will be used to outline the 3D contours of liver masses, which will then be refined by radiologists and hepatobiliary-pancreatic surgeons to enhance model accuracy. By incorporating more imaging data, the model's recognition capabilities will be improved, laying the groundwork for prospective clinical trials and aiming to establish a superior AI model for early liver cancer screening based on CT imaging.

Начало: 15.07.2025 Край: 15.09.2030 Възраст: 18–80 г.

China Zhejiang University NCT06859840

1 … 200 201 202 203 204 … 240